SMARCC1 and early-onset autosomal dominant Alzheimer disease: STMN1, SMARCC1, ALDOA, CLTC, PSMG1, SUZ12, DAG1, PGRMC1, and HMGCR, and MYO10 were upregulated following compound treatment Additionally, the compounds against Alzheimer’s disease were identified and their BBB permeability levels were predicted.